Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NUBEQA significantly reduced the risk of death by 31%, offering men with non-metastatic castration-resistant prostate cancer (nmCRPC) extended survival for a greater chance of living longer.
Product Name : Nubeqa
Product Type : HPAPI
Upfront Cash : Inapplicable
August 01, 2021
Lead Product(s) : Darolutamide
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable